Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | HINT1 | P49773 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | POLA1 | P09884 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6875722 | 0.80 | TYMP (0.41) | ALDH1A1BCHEACHE | |
| SCHEMBL7699861 | 0.78 | TK1 (0.45) | BCHE | |
| SCHEMBL7707747 | 0.77 | TDP1 (0.40) | MEN1KMT2ANT5E | |
| SCHEMBL6874990 | 0.74 | TAS1R3 (0.42) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL7699092 | 0.74 | TAS1R3 (0.42) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL6877611 | 0.74 | TAS1R3 (0.42) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL25410125 | 0.72 | ALDH1A1 (0.63) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL8593102 | 0.72 | ALDH1A1 (0.63) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A | |
| SCHEMBL2027278 | 0.72 | TAS1R3 (0.80) | TAS1R3TAS1R1MEN1KMT2ATSHR | |
| SCHEMBL8970362 | 0.71 | TAS1R3 (0.60) | TAS1R3TAS1R1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833361-B2 | Compound for use in the treatment of viral diseases | RIBAPHARM, INC. | 2004-12-21 | — | — | US | disclosed |
| US-20030028013-A1 | Novel nucleosides having bicyclic sugar moiety | CEQUENT PHARMACEUTICALS, INC. | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030028013-A1 | Novel nucleosides having bicyclic sugar moiety | DCK, NUDT14, UCK2 | TAS1R3 4198/4885TAS1R1 4298/4885ALDH1A1 3461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.